Abiopharma

🔍 Kugel Janina (Executive)

Company: Kyndryl Holdings, Inc. (KD)

Report Date: 2026-07-30

Detailed Transactions and Holdings:

• Acquired 17,844 shares of Common Stock at $13.45 per share (Direct)
  Date: 2026-07-30 | Code: A | equity_swap_involved: 0 | shares_owned_after: 66,154.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 882 shares of Common Stock at $13.45 per share (Direct)
  Date: 2026-07-30 | Code: F | equity_swap_involved: 0 | shares_owned_after: 65,272.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Represents a grant of restricted stock units which will vest in full on the earlier of the anniversary of the grant date and the date of the Issuer's 2027 Annual Meeting of Stockholders (provided that the date of such annual meeting is at least 50 weeks after the date of the Issuer's 2026 Annual Meeting of Stockholders).
• F2: Represents the withholding from delivery of shares of Common Stock from the Issuer to satisfy the Reporting Person's tax withholding obligation upon the vesting of 6,296 restricted stock units previously granted on July 31, 2025 to the Reporting Person. These shares of Common Stock were not sold by the Reporting Person but were instead offset from the total number of vested shares of Common Stock received by the Reporting Person from the Issuer.
• REMARKS: Exhibit List - Exhibit 24.1 - Power of Attorney